Synonyms: Thymalfasine; Thymalfasinum; Thymosin α1; Timalfasina.
Cyrillic synonym: Тимальфазин.

💊 Chemical information

CAS — 62304-98-7; 69521-94-4.

💊 Profile

Thymalfasin is a thymus hormone found in thymosin fraction 5 (a crude thymus gland extract) but now produced by synthesis. Thymalfasin is used alone or with interferon as an im munomodulator for the treatment of chronic hepatitis B, and with interferon for hepatitis C. It is given by subcutaneous injection in a dose of 1.6 mg twice weekly for up to 12 months. The dose in patients who weigh less than 40 kg is 40 micrograms/kg. Thymalfasin is also used to enhance the effectiveness of influenza vaccines in immunocompromised or elderly patients and of influenza and hepatitis B vaccines in chronic haemodialysis patients. Thymalfasin is under investigation for a number of other diseases, including hepatitis D, hepatocellular carcinoma, non-small cell lung cancer, melanoma, and HIV infection and AIDS.
1. Garaci E, et al. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-
α1 and interferon-α2a. Eur J Cancer 1995; 31A: 2403–5.
2. Rasi G, et al. Combination thymosin α and lymphoblastoid interferon treatment in chronic hepatitis C. Gut 1996; 39: 679–83
3. Zavaglia C, et al. A pilot study of thymosin-α1 therapy for chronic hepatitis D. J Clin Gastroenterol 1996; 23: 162–3
4. Andreone P, et al. A randomized controlled trial of thymosin-α versus interferon alfa treatment in patients with hepatitis B e antigen antibody- and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 1996; 24: 774–7
5. Sherman KE, et al. Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 1998; 27: 1128–35
6. Chien R-N, et al. Efficacy of thymosin α1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998; 27: 1383–7
7. Rasi G, et al. Combined treatment with thymosin-α1 and low dose interferon-α after dacarbazine in advanced melanoma. Melanoma Res 2000; 10: 189–92
8. Ancell CD, et al. Thymosin alpha-1. Am J Health-Syst Pharm 2001; 58: 879–85
9. Andreone P, et al. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. J Viral Hepatitis 2004; 11: 69–73
10. Sjogren MH. Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol 2004; 19: S69–S72
11. Rustgi V. Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. J Gastroenterol Hepatol 2004; 19: S76–S78
12. Iino S, et al. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J Viral Hepatitis 2005; 12: 300–306.

💊 Preparations

Proprietary Preparations

Arg.: Zadaxin; Hong Kong: Zadaxin; Indon.: Zadaxin; Ital.: Zadaxin; Malaysia: Zadaxin; Mex.: Zadaxin; Philipp.: Zadaxin; Singapore: Zadaxin; Thai.: Zadaxin†.
Published May 08, 2019.